Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100375 | 0.90 | LMNA (0.52) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6087608 | 0.87 | SMN1; SMN2 (0.65) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6089371 | 0.80 | CA1 (0.50) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6087654 | 0.80 | CA1 (0.50) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| Batabulin SCHEMBL18845 | 0.80 | LMNA (0.54) | LMNASMN1; SMN2HTTKMT2AMEN1 | |
| Batabulin SCHEMBL29373304 | 0.80 | LMNA (0.54) | LMNASMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL6681299 | 0.80 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6088076 | 0.79 | CA1 (0.49) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6673889 | 0.79 | LMNA (0.58) | LMNASMN1; SMN2HTTALOX15MAPK1 | |
| SCHEMBL6086613 | 0.79 | CA1 (0.49) | LMNASMN1; SMN2HTTALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090014-B1 | ARYLSULFONANILIDE PHOSPHATES | TULARIK INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6417176-B2 | ANTICANCER AGENTS, PSORIASIS, RESTENOSIS, ATHEROSCLEROSIS | TULARIK, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20010018430-A1 | Arylsulfonanilide phosphates | TULARIK, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-1090014-A1 | ARYLSULFONANILIDE PHOSPHATES | Tularik Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6211167-B1 | ANTICHOLESTEROL, ANTIPROLIFERATIVE AND ANTILIPEMIC AGENTS; CANCER, PSORIASIS, ATHEROSCLEROSIS, INFECTION AND VASCULAR RESTENOSIS TREATMENT | TULARIK INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1999067258-A1 | ARYLSULFONANILIDE PHOSPHATES | TULARIK INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018430-A1 | Arylsulfonanilide phosphates | PIK3CA, INPP5D, INPPL1 | LMNA 3419/4885SMN1; SMN2 4755/4885HTT 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.